Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016081746 - ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

Publication Number WO/2016/081746
Publication Date 26.05.2016
International Application No. PCT/US2015/061632
International Filing Date 19.11.2015
IPC
C07K 16/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 39/3955
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
3955against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 47/6803
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
A61P 37/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US]
Inventors
  • LONBERG, Nils
  • KORMAN, Alan, J.
  • SELBY, Mark, J.
  • BARNHART, Bryan C.
  • YAMNIUK, Aaron, P.
  • SRINIVASAN, Mohan
  • HENNING, Karla A.
  • HAN, Michelle, Minhua
  • LEI, Ming
  • SCHWEIZER, Liang
  • HATCHER, Sandra, V.
  • RAJPAL, Arvind
Agents
  • REMILLARD, Jane, E.
Priority Data
62/083,02121.11.2014US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
(FR) ANTICORPS COMPRENANT DES RÉGIONS CONSTANTES DE CHAÎNE LOURDE MODIFIÉES
Abstract
(EN) Provided herein are heavy chain constant regions (referred to as "modified heavy chain constant regions"), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
(FR) L'invention concerne des régions constantes de chaîne lourde (désignées ici par "régions constantes de chaîne lourde modifiées"), ou des fragments fonctionnellement équivalents de celles-ci, qui améliorent les propriétés biologiques d'anticorps par rapport à celles des mêmes anticorps sous forme non modifiée. Un exemple de région constante de chaîne lourde modifiée comprend une charnière d'IgG2 et trois domaines constants (à savoir, les domaines CH1, CH2 et CH3), dans lesquels un ou plusieurs des domaines de région constante sont d'un isotype non-IgG2 (par exemple, IgG1, IgG3 ou IgG4). La région constante de chaîne lourde peut comprendre des séquences de domaine d'IgG humaine de type sauvage, ou des variants de ces séquences. L'invention concerne également des procédés permettant d'améliorer certaines propriétés biologiques d'anticorps qui comprennent une charnière non-IgG2, comme l'internalisation, l'effet agoniste et l'effet antagoniste, lequel procédé comprend le remplacement de la charnière non-IgG2 de l'anticorps par une charnière d'IgG2.
Latest bibliographic data on file with the International Bureau